BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$2.35−0.21 (-8.20%)

Close on Nov 12, 2026Market cap $188.41MP/E –Yield –

BridgeBio Oncology Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

BridgeBio Oncology Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?